Biocon Limited
NYSE
Biocon Limited's latest marketcap:
As of 06/06/2025, Biocon Limited's market capitalization has reached $4.6 B. According to our data, Biocon Limited is the 3431th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.6 B |
| Revenue (ttm) | 1.78 B |
| Net Income (ttm) | 118.1 M |
| Shares Out | 1.2 B |
| EPS (ttm) | 0.1 |
| Forward PE | 48.76 |
| Ex-Dividend Date | 07/04/2025 |
| Earnings Date | 07/30/2025 |
Biocon Limited's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | ₹395.01 B | -9.51% |
| 12/31/2024 | ₹437.25 B | 46.69% |
| 12/29/2023 | ₹298.08 B | -4.59% |
| 12/30/2022 | ₹312.41 B | -27.97% |
| 12/31/2021 | ₹433.73 B | -21.37% |
| 12/31/2020 | ₹551.59 B |
Company Profile
About Biocon Limited
Biocon Limited, along with its subsidiaries, is a leading biotechnology company specializing in the manufacture and sale of biopharmaceutical products and research services. Operating globally, the company serves markets in India, Brazil, Singapore, and other international regions.
Business Segments
Biocon operates through four key segments:
- Generics: Offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis treatments, anti-cancer/oncology drugs, and other therapeutic solutions.
- Novel Biologics: Focuses on innovative biologics such as head and neck cancer treatments and psoriasis molecules.
- Biosimilars: Provides biosimilar products like insulins, trastuzumab, pegfilgrastim, and bevacizumab.
- Research Services: Delivers integrated discovery, development, and manufacturing services for pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical industries.
Company Overview
Founded in 1978, Biocon Limited is headquartered in Bengaluru, India. The company is recognized for its contributions to biotechnology and pharmaceutical innovation, catering to diverse healthcare needs worldwide.
Frequently Asked Questions
-
What is Biocon Limited's (NSE-BIOCON) current market cap?As of 06/06/2025, Biocon Limited (including the parent company, if applicable) has an estimated market capitalization of $4.6 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Biocon Limited (NSE-BIOCON) rank globally by market cap?Biocon Limited global market capitalization ranking is approximately 3431 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.